|
Home > Analytics & Media > Press Releases > August 01, 2013 - Prix Galien Russia 2013 Nominees for “Best Research in Russia” ...
Prix Galien Russia 2013 Nominees for “Best Research in Russia,” “Best Pharmaceutical Agent” and “Best Biotechnology Product” announced.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DIASKINTEST® | CSJC “GENERIUM” |
| MM-D37K® | Metamax Ltd |
| SkQ – mitochondrially targeted antioxidant (Visomitin ®) | Mitotech LLC |
| OM-RCA-01® | Oncomax Ltd |
| C12-OB® | Pharma Bio LLC |
| Timodepressin® | Pharma Bio LLC |
| Inhibitor of the HIV virus matrixprotein p17/MA® | Quantum Pharmaceuticals LLC |
| Modular nanotransporters® | Russian Academy of Sciences Professor Alexander S. Sobolev, Head, Laboratory of Molecular Genetics of Intracellular Transport Institute of Gene Biology |
Best Pharmaceutical Agent (Nominees)
| TICAGRELOR (BRILINTA®) | AstraZeneca |
| Sorafenib (Nexavar ®) | Bayer HealthCare |
| Iloprost (Ventavis ®) | Bayer HealthCare |
| Rivaroxaban (Xarelto ®) | Bayer HealthCare |
| Ethinylestradiol + Drospirenone + Levomefolate Calcium (Yaz Plus ®) | Bayer HealthCare |
| Estradiol Valerate (Qlaira ®) | Bayer HealthCare |
| Dienogest (Visanne ®) | Bayer HealthCare |
| Dabigatran etexilat (Pradaxa®) | Boehringer Ingelheim |
| Telaprevir (INCIVO ®) | JANSSEN pharmaceutica |
| Abiraterone (ZYTIGA ®) | JANSSEN pharmaceutica |
| Pemetrexed (Alimta®) | Eli Lilly |
| Sitagliptin+metformin (Janumet ®) | MSD Pharmaceuticals |
| Raltegravir (Isentress ®) | MSD Pharmaceuticals |
| Everolimus (Afinitor ®) | Novartis Pharma |
| Vildagliptin (Galvus ®) | Novartis Pharma |
| Fingolimod (Gilenya ®) | Novartis Pharma |
| Nilotinib (Tasigna ®) | Novartis Pharma |
| Agomelatine (Valdoxan ®) | Les Laboratoires Servier |
| IVABRADINE (Coraxan ®) | Les Laboratoires Servier |
| Roflumilast (Daxas ®) | Takeda |
Best Biotechnology Product (Nominees)
| Adalimumab (Humira®) | AbbVie |
| Denosumab (Xgeva®) | Amgen |
| Abatacept (ORENCIA®) | Bristol-Myers Squibb |
| Teriparatide (Forsteo®) | Eli Lilly |
| Cetuximab (Erbitux®) | Merck Serono, division of Merck |
| Epoetin alfa (Binocrit®) | Sandoz |
| Canakinumab (Ilaris®) | Novartis Pharma |
| ranibizumab (Lucentis®) | Novartis Pharma |
| Tocilizumab (ACTEMRA®) | F.Hoffmann-La Roche Ltd. |
The Prix Galien Russia Committee comprised of nine renowned leaders in biomedical research is responsible for evaluating nominees. Winners will be honored at the Prix Galien Russia Award Ceremony in the SwissÔtel convention center, on the 24th of October 2013.
“This first Edition of the Prix Galien Russia can already be considered a success, looking at the number and variety of candidates and the quality of the Jury”, remarked Frédéric Boucheseiche, General Secretary of the Prix Galien Russia. “We are proud to honor those that drive progress in medical science and improve human condition through their innovations, research efforts and dedication.”
About Prix Galien Russia:
The Prix Galien Russia will be inaugurated in Moscow, Russia in 2013 under the auspice of an exceptional awards committee composed of eminent specialists involved in the sphere of Russian and international pharmaceutical research.
Around the world, the Prix Galien awards outstanding achievements in improving the global human condition through the development of innovative therapies.
To attend or support the Prix Galien 2013 awards ceremony or sponsor opportunities, please contact Crystelle Coury: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it